martes, 6 de febrero de 2024

Durvalumab Plus Bevacizumab Improves TACE Outcomes in HCC M. Alexander Otto, PA, MMS

https://www.medscape.com/viewarticle/durvalumab-plus-bevacizumab-improves-tace-outcomes-hcc-2024a10002l2?src=

No hay comentarios:

Publicar un comentario